Literature DB >> 29441465

Xylanilyticolides A-C, Three New Compounds from Cultures of the Actinomycete Promicromonospora xylanilytica YIM 61515.

Zhen-Xiong Wang1, Shen Qin2, Li-Hua Xu2, He-Ping Chen1, Huan Sun1, Rong Huang1, Zheng-Hui Li1, Tao Feng3, Ji-Kai Liu4.   

Abstract

Three new lactones, xylanilyticolides A-C (1-3), were isolated from cultures of the actinomycete Promicromonospora xylanilytica YIM 61515. Their structures were elucidated by 1D and 2D NMR spectroscopic data in conjunction with HRESIMS analysis. Compound 1 exhibited potent cytotoxicities against five human cancer cell lines HL-60, A-549, SMMC-7721, MCF-7 and SW480 with the IC50 values of 3.9, 15.2, 11.2, 5.9, and 4.7 μM, respectively.

Entities:  

Keywords:  Actinomycete; Cytotoxicity; Promicromonospora xylanilytica; Xylanilyticolides

Year:  2018        PMID: 29441465      PMCID: PMC5913047          DOI: 10.1007/s13659-018-0154-1

Source DB:  PubMed          Journal:  Nat Prod Bioprospect        ISSN: 2192-2209


Introduction

Actinomycetes are well-known for their ability to produce natural products with structural complexity and diverse biological activities [1, 2]. Salinomycin, isolated from the culture broth of an actinomycete strain of Streptomyces, shows remarkable toxicity for cancer stem cells [3, 4]. Actinomycetes, including some rare genera of actinomycetes [5], are also valuable sources in the discovery of natural antibiotics [6]. Since the genus Promicromonospora was proposed by Krasil’nikov et al. in 1961 [7], there has been only one report of chemical investigation on this genus with discovery of a novel macrocyclic dilactone from Promicromonospora sp. RL26 in 2011 [8]. Herein, the investigation of secondary metabolites from the Promicromonospora xylanilytica YIM 61515 led to the discovery of three new products, xylanilyticolides A–C (1–3) (Fig. 1) [9]. Their structures were elucidated by analyses of 1D and 2D NMR spectroscopic methods. Their cytotoxicities against five human cancer cell lines were evaluated. Report herein are the isolation, structural elucidation and cytotoxicities of them.
Fig. 1

Structures of compounds 1–3

Structures of compounds 1–3

Results and Discussion

Structural Elucidation of Xylanilyticolides A–C (1–3)

Xylanilyticolide A (1), obtained as colorless oil, had a formula of C26H42O7 deduced by HRESIMS sodium adduct ion peak at m/z 489.2822 [M + Na]+ (calcd. for C26H42O7Na, 489.2823), requiring six degrees of unsaturation. The 1H NMR data displayed three methyl singlets at δH 1.84 (H-9′), 1.52 (H-16), 3.44 (OMe), three methyl doublets at δH 1.54 (H-13, d, J = 6.2 Hz), 1.09 (H-14, d, J = 6.6 Hz), 0.77 (H-15, d, J = 6.6 Hz), and two olefinic protons at δH 5.81 (H-2′, d, J = 15.7 Hz), 7.34 (H-3′, d, J = 15.7 Hz). The 13C NMR and DEPT spectra (Table 1) exhibited signals for 26 carbon atoms, including two carbonyls (δC 165.9, 169.5), six olefinic carbons (δC 115.3, 120.2, 134.4, 134.8, 143.7, 151.1), six methyls (δC 12.8, 13.5, 15.7, 16.1, 20.7, 57.3). The above data coupled with a literature survey indicated that compound 1 was analogous to the reported compound rasfonin, an apoptosis inducer in Ras-dependent cells isolated from the fungus Talaromyces sp. [10]. Comparing with the reported structure, the two distinct differences in compound 1 were the reduction of olefinic bond in C-3 and the substitution of a methoxy in C-4. The 1H-1H COSY correlations between H-3 (δH 2.79, 2.67)/H-4 (δH 3.70), H-4/H-5 (δH 5.29), and HMBC correlation from –OCH3 (δH 3.44) to C-4 (δC 74.1), from H-3 (δH 2.79, 2.67) and H-4 to C-2 (δC 169.5) supported these changes (Fig. 2).
Table 1

1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data of 1–3 (δ in ppm, J in Hz)

No.1 (CDCl3)2 (acetone-d6)3 (methanol-d4)
δC, type δ H δC, type δ H δC, type δ H
2169.5, C176.8, C179.5, C
332.8, CH22.79 (17.8, 5.5)28.8, CH22.53, ddd (17.5, 9.5, 9.5)29.3, CH22.58, ddd (17.5, 10.0, 8.9)
2.67 (17.8, 3.2)2.47, ddd (17.5, 9.5, 4.5)2.49, overlapped
474.1, CH3.70, ddd (5.5, 3.2, 3.2)25.2, CH22.38, m; 1.98, m25.5, CH22.35, m; 1.95, m
566.1, CH5.29, dd (3.2, 1.5)80.5, CH4.79, ddd (7.4, 7.4, 6.5)81.9, CH4.81, ddd (7.4, 7.4, 6.4)
681.3, CH4.31, dd (8.7, 1.5)76.7, CH5.06, dd (6.5, 4.0)77.3, CH5.04, dd (6.4, 4.0)
731.7, CH1.99, m31.9, CH2.03, m32.4, CH2.01, overlapped
840, CH21.22, br. dd (13.3, 5.0)41.7, CH21.36, ddd (14.4, 7.6, 6.3)41.9, CH21.37, m
1.01, ddd (13.3, 9.0, 3.8)0.94, m0.91, m
927.9, CH1.67, m28.3, CH1.79, m28.7, CH1.75, m
1046.4, CH22.00, overlapped48.5, CH21.97, overlapped29.6, CH21.92, overlapped
1.44, dd (13.1, 9.8)1.68, dd (13.0, 8.5)1.72, m
11134.4, C135.2, C135.5, C
12120.2, CH5.12, q (6.2)120.5, CH5.15, q (6.6)121.0, CH5.15, q (6.6)
1313.5, CH31.54, d (6.2)13.4, CH31.52, d (6.6)13.5, CH31.53, d (6.6)
1416.1, CH31.09, d (6.6)15.6, CH30.98, d (6.8)15.7, CH30.99, d (6.8)
1520.7, CH30.77, d (6.6)20.2, CH30.82, d (6.5)20.4, CH30.84, d (6.3)
1615.7, CH31.52, s15.6, CH31.54, s15.7, CH31.54, s
1′165.9, C167.0, C168.5, C
2′115.3, CH5.81, d (15.7)116.2, CH5.87, d (15.7)115.9, CH5.85, d (15.6)
3′151.1, CH7.34, d (15.7)150.9, CH7.34, d (15.7)150.3, CH7.34, d (15.6)
4′134.8, C134.7, C133.1, C
5′143.7, CH5.78, d (10.0)145.6, CH5.84, d (10.0)152.2, CH5.73, d (10.0)
6′39.4, CH2.89, m39.8, CH2.89, m36.2, CH2.52, m
7′34.9, CH21.80, m; 1.61, m35.7, CH21.82, m; 1.48, m31.1, CH21.46, m; 1.33, m
8′60.8, CH23.74, m; 3.61, overlapped60.4, CH23.59, m; 3.49, m12.3, CH30.87, t (7.4)
9′12.8, CH31.84, s12.8, CH31.87, s12.6, CH31.83, s
10′66.0, CH23.63, overlapped66.0, CH23.53, s, 2H20.5, CH31.02, d (6.6)
3.58, overlapped
–OMe57.3, CH33.44, s
Fig. 2

Key 2D NMR correlations of compounds 1 and 2

1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data of 1–3 (δ in ppm, J in Hz) Key 2D NMR correlations of compounds 1 and 2 Δ2′ was established as E configuration, which could be confirmed by the coupling constant (see Table 1). Verified by the ROESY correlation between H-3′ (δH 7.34)/H-5′ (δH 5.78), Δ4′ could identified as E configuration. Δ11 was E configuration, which could be identified by the H-12 (δH 5.12)/H-10 (δH 2.00, 1.44) ROESY correlation. From the Newman projection (Fig. 3), the JH-3/H-4 of 3.2 Hz and 5.5 Hz, JH-4/H-5 of 3.2 Hz, JH-6/H-5 of 1.5 Hz as well as H-5/H-6 ROESY correlation were observed, which could confirmed the relative configuration of the lactone ring as 4S*, 5R*, 6R*. However, the stereoconfigurations of C-7, C-9, and C-6′ can’t be determined by the ROESY experiment. The calculated ECD and single crystal X-ray diffraction were also in failure. Therefore, the structure of compound 1 was deduced as xylanilyticolide A.
Fig. 3

Newman projection and key ROESY correlations in compound 1

Newman projection and key ROESY correlations in compound 1 Compound 2 was obtained as colorless oil. Its molecular formula was assigned as C25H40O6 by HRESIMS ion peak at m/z 459.2723 [M + Na]+ (calcd. for C25H40O6Na, 459.2717), implying the presence of six degrees of unsaturation. The 1H NMR spectrum of 2 illustrated the presence of two methyl singlets at δH 1.54 (H-16) and 1.87 (H-9′); two oxygenated methylenes at δH 3.59/3.49 (H-8′), 3.53 (H-10′); four olefinic protons at δH 5.87 (H-2′), 7.34 (H-3′), 5.84 (H-5′), 5.15 (H-12); and two oxygenated methines at δH 4.79 (H-5), 5.06 (H-6). Combined 13C NMR data (Table 1) and HSQC spectrum indicated the presence of five methyls, seven methylenes, five saturated methines, four olefinic methines, two fully substituted carbons (δC 135.2 and 134.7), and two ketone carbons (δC 176.8 and 167.0). The 1H and 13C chemical shifts of compound 2 (Table 1) were highly similar to those of 1, except the δ-lactone moiety in 1 was replaced by a γ-lactone moiety in 2, which could be verified by the HMBC correlation between H-5 (δH 4.79)/C-2 (δC 176.8) and 1H-1H COSY correlations of H-6 (δH 5.06)/H-5 (δH 4.79), H-5 (δH 4.79)/H-4 (δH 2.38, 1.98), H-4 (δH 2.38, 1.98)/H-3 (δH 2.53,2.47) of compound 2 (Fig. 2). The E/Z configurations of the double bonds in compound 2 were deduced as the same with those of compound 1 by ROESY correlations of H-9′ with H-6′ and H-10′. However, the stereochemistry of C-7, C-9, and C-6′ can’t be established currently. The structure of compound 2 was, therefore, identified as xylanilyticolide B. The molecular of compound 3 was established by HRESIMS ion peak at m/z 427.2817 [M + Na]+ (calcd. for C25H40O4Na, 427.2819). Detailed analyses of 1H and 13C NMR data of compound 3 revealed that compound 3 had the same skeleton with that of compound 2. The main difference was that C-8′ and C-10′ in compound 3 was two methyl carbons rather than two hydroxymethyl groups in 2. Detailed analysis of 2D NMR data suggested that other parts of 3 were the same to those of 2. Hence the structure of 3 was elucidated as xylanilyticolide C.

Cytotoxicity Assays

Compounds 1–3 were evaluated for their cytotoxicity activity utilizing an MTS cytotoxicity assay in vitro (DDP was used as a positive control). Compound 1 showed potent inhibitory activity against HL-60, A-549, SMMC-7721, MCF-7 and SW480 cells lines with the IC50 values of 3.9, 15.2, 11.2, 5.9, 4.7 μM, respectively (Table 2), while compounds 2 and 3 showed no significant cytotoxicity activity under the concentration of 40 μM.
Table 2

Cytotoxicities of 1 against five human cancer cell lines (IC50 μM)

CompoundHL-60A-549SMMC-7721MCF-7SW480
1 3.915.211.25.94.7
DDPa4.627.428.029.330.0

aPositive control

Cytotoxicities of 1 against five human cancer cell lines (IC50 μM) aPositive control

Experimental

General Experimental Procedures

Optical rotations were recorded on a JASCO P-1020 digital polari-meter (Horiba, Kyoto, Japan). UV/Vis spectra were obtained using a Shimadzu UV2401PC spectrometer (Shimadzu, Kyoto, Japan). 1D and 2D NMR spectra were measured on a Bruker Avance III 600 MHz spectrometers (Bruker Biospin GmbH, Karlsruhe, Germany). HRESIMS were recorded on an Agilent 6200 Q-TOF MS system (Agilent Technologies, Santa Clara, CA, USA). Silica gel (200–300 mesh, Qingdao Haiyang Chemical Co., Ltd., P. R. China) was used for chromatography column. Size exclusion chromatography was performed on Sephadex LH-20 (GE, Healthcare) columns. MPLC separation was conducted on a Biotage Isolera One using a Spherical C18 column. Semi-preparative HPLC was performed on an Agilent 1260 liquid chromatography system equipped with Zorbax SB-C18 columns (9.4 mm × 150 mm, particle size 5 μm).

Actinomycete Materials and Culture Condition

The strain was identified as P. xylanilytica YIM 61515 by Prof. Shen Qin of Yunnan University. A voucher strain (HFC: 20160920-4A) was deposited at the School of Pharmaceutical Sciences, South-Central University for Nationalities, China. The P. xylanilytica YIM 61515 strain was cultured in seed medium (glucose 20 g, peptone 2 g, yeast extract 2 g, soluble starch 5 g, K2HPO4 0.5 g, MgSO4 0.5 g, NaCl 4 g, CaCO3 2 g in 1 L of deionized water, the pH was adjusted to 7.8 before autoclaving) at 25 °C with shaking at 150 rpm for 7 days. Then inoculated the seed culture into 50 Erlenmeyer flasks (500 mL), previously sterilized by autoclaving, each containing 100 g of rice and 100 mL of distilled water. All flasks were incubated at 25 °C for 70 days.

Extraction and Isolation

Each flask added 200 mL of EtOAc, and the culture was homogenized. The suspension was extracted repeatedly with EtOAc (4 × 10 L), and the organic layer was evaporated to dryness under vacuum to yield a crude extract (49 g), which was fractionated by MPLC with a stepwise gradient of MeOH/H2O (v/v 10:90, 40:60, 70:30, 90:10, 100:0) to give nine fractions (Fr. A–J). Fr. D (1.87 g) was subjected to 200–300 mesh silica gel column with stepwise elution petroleum ether–EtOAc (8:1–2:1) to obtain nine sub-fractions (D1–D9) based on TLC analyses. The third fraction Fr. D3 was purified by semi-preparative HPLC using a gradient elution (MeCN/H2O 50:50 2.5 mL/min) to give compound 1 (4.4 mg, colorless oil). Fr. E (508 mg) was separated on Sephadex LH-20 (MeOH) to give four fractions (E1–E4), and compound 2 (3.9 mg) was obtained from Fr. E2 (66.9 mg) which purified with semi-preparative HPLC using an isocratic elution (MeCN/H2O 55:45, 3 mL/min). Fr. F (1.9 g) was subjected to 200–300 mesh silica gel column eluting with petroleum ether–EtOAc 4:1 to give 5 fractions (F1–F5). Fr. F3 (98.4 mg) was subjected to semi-prep HPLC with isocratic elution (MeCN/H2O 90:10, 3 mL/min) to give compound 3 (0.8 mg). Xylanilyticolide A (1) colorless oil, [α]D24 8.2 (c 0.11, MeOH); UV (MeOH) λ max(log ε) 202 (3.90), 269 (4.31) nm; 1H and 13C NMR data, see Table 1. HRESIMS m/z 489.2822 [M + Na]+ (calcd. for C26H42O7Na, 489.2823). Xylanilyticolide B (2) colorless oil, [α]D24 1.7 (c 0.13, MeOH); UV (MeOH) λ max(log ε) 202 (3.85), 268 (4.31) nm; 1H and 13C NMR data, see Table 1. HRESIMS m/z 459.2723 [M + Na]+ (calcd. for C25H40O6Na, 459.2717). Xylanilyticolide C (3) colorless oil, [α]D24 4.5 (c 0.07, MeOH); UV (MeOH) λ max(log ε) 202 (3.15), 262 (3.77), 544 (1.35) nm; 1H and 13C NMR data, see Table 1. HRESIMS m/z 427.2817 [M + Na]+ (calcd. for C25H40O4Na, 427.2819).

Cytotoxicity

Five human cancer cell lines, breast cancer SK-BR-3, hepatocellular carcinoma SMMC-7721, human myeloid leukemia HL-60, pancreatic cancer PANC-1, and lung cancer A-549 were used. Cells were cultured in RPMI-1640 or in DMEM medium (Hyclone, Logan, UT, USA), supplemented with 10% fetal bovine serum (Hyclone, USA) in 5% CO2 at 37 °C. The cytotoxicity assay was performed according to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method in 96-well microplates [11]. Briefly, 100 µL of adherent cells were seeded into each well of 96-well cell culture plates and allowed to adhere for 12 h before addition of test compounds, while suspended cells were seeded just before drug addition with initial density of 1 × 105 cells/mL. Each tumor cell line was exposed to the test compound at concentrations of 0.0625, 0.32, 1.6, 8, and 40 μM in triplicates for 48 h, and all tests were done in twice with cisplatin (Sigma, Los Angeles, USA) as a positive control. After compound treatment, cell viability was detected and a cell growth curve was graphed. IC50 values were calculated by Reed and Muench’s method [12]. Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 3875 kb)
  10 in total

Review 1.  Rare genera of actinomycetes as potential producers of new antibiotics.

Authors:  A Lazzarini; L Cavaletti; G Toppo; F Marinelli
Journal:  Antonie Van Leeuwenhoek       Date:  2000-12       Impact factor: 2.271

Review 2.  New antibiotics from bacterial natural products.

Authors:  Jon Clardy; Michael A Fischbach; Christopher T Walsh
Journal:  Nat Biotechnol       Date:  2006-12       Impact factor: 54.908

3.  Isolation of a novel macrocyclic dilactone-JBIR-101-from Promicromonospora sp. RL26.

Authors:  Miho Izumikawa; Motoki Takagi; Kazuo Shin-Ya
Journal:  J Antibiot (Tokyo)       Date:  2011-08-03       Impact factor: 2.649

Review 4.  Diversity, abundance and natural products of marine sponge-associated actinomycetes.

Authors:  Usama Ramadan Abdelmohsen; Kristina Bayer; Ute Hentschel
Journal:  Nat Prod Rep       Date:  2014-03       Impact factor: 13.423

5.  Salinomycin, a new polyether antibiotic.

Authors:  Y Miyazaki; M Shibuya; H Sugawara; O Kawaguchi; C Hirsoe
Journal:  J Antibiot (Tokyo)       Date:  1974-11       Impact factor: 2.649

Review 6.  Actinomycetes: still a source of novel antibiotics.

Authors:  Olga Genilloud
Journal:  Nat Prod Rep       Date:  2017-10-18       Impact factor: 13.423

7.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

8.  Promicromonospora xylanilytica sp. nov., an endophytic actinomycete isolated from surface-sterilized leaves of the medicinal plant Maytenus austroyunnanensis.

Authors:  Sheng Qin; Ji-Hong Jiang; Hans-Peter Klenk; Wen-Yong Zhu; Guo-Zhen Zhao; Li-Xing Zhao; Shu-Kun Tang; Li-Hua Xu; Wen-Jun Li
Journal:  Int J Syst Evol Microbiol       Date:  2011-02-18       Impact factor: 2.747

9.  Eleven new 2-pyrones from a Fungi Imperfecti, Trichurus terrophilus, found in a screening study guided by immunomodulatory activity.

Authors:  Haruhiro Fujimoto; Yoshie Okamoto; Eriko Sone; Satomi Maeda; Kohki Akiyama; Masami Ishibashi
Journal:  Chem Pharm Bull (Tokyo)       Date:  2005-08       Impact factor: 1.645

10.  Identification of selective inhibitors of cancer stem cells by high-throughput screening.

Authors:  Piyush B Gupta; Tamer T Onder; Robert A Weinberg; Eric S Lander; Guozhi Jiang; Kai Tao; Charlotte Kuperwasser
Journal:  Cell       Date:  2009-08-13       Impact factor: 41.582

  10 in total
  1 in total

1.  Three New Compounds from the Actinomycete Actinocorallia aurantiaca.

Authors:  Kai-Yue Han; Xing Wu; Chenglin Jiang; Rong Huang; Zheng-Hui Li; Tao Feng; He-Ping Chen; Ji-Kai Liu
Journal:  Nat Prod Bioprospect       Date:  2019-09-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.